Therefore, testing for the mutation in the EGFR gene and understanding its prevalence is mandatory to be identified in the patients with NSCLC as it will alter the prognosis, nature of the treatment, the pattern of progression and the overall outcome [22,27]. Here, EGFR is linked to non-small cell lung carcinoma.